£74.80

Humana Immunosuppression and Human Malignancy (Contemporary Immunology)

Price data last checked 36 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

About as cheap as it gets. The only time it was cheaper was 1 month ago.

£75 today · all-time low £74 (May 2026) · usually the usual

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey
↓ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 55 days • 55 data points (No recent data available)

Historical
Generating forecast...
£75.53 £74.07 £74.39 £74.71 £75.02 £75.34 £75.66 05 April 2026 18 April 2026 02 May 2026 15 May 2026 29 May 2026

Price Distribution

Price distribution over 55 days • 3 price levels

Days at Price
Current Price
11 days 6 days · current 38 days 0 10 19 29 38 £74 £75 £76 Days at Price

Price Analysis

Most common price: £76 (38 days, 69.1%)

Price range: £74 - £76

Price levels: 3 different prices over 55 days

Description

The immune system can deal effectively with the majority of viruses and bacteria, less effectively with parasites, and very poorly with cancer. Why is this so? Why are McFarlane Burnet's and Lewis Thomas' predictions that the immune system is in volved in ridding the body of cancer cells, encapsulated in the catchy phrase "immunologic surveillance," so difficult to experi mentally establish? Cancer differs from infectious agents in being derived from the host. Hence, it has been postulated that cancer cells lack anti gens that the immune system can recognize. They are not "im munogenic. " However, this argument is seriously weakened by the existence of numerous human autoimmune diseases, in which the immune system effectively recognizes and attacks a va riety of self tissues. Thus, the potential clearly exists for recogni tion of the surfaces of tumor cells. Professor Naor and his colleagues have written a book that explores another possible reason: cancer cells are recognized by the immune system-but is it possible that the consequence of recognition is inhibition of the immune system-by suppressor T cells or macrophages? The evolution of the malignant state may only occur in individuals who develop this suppression. This book reviews the evidence that suppressor cells, poorly characterized and difficult to study, may be of fundamental im portance in cancer. In fact, our incapacity to understand the na ture of suppressor cells and their mode of action is one of the ma jor problems in immunology research today.

Product Specifications

Brand
Humana
Format
paperback
Domain
Amazon UK
Publication Date
30 September 2011
Listed Since
21 December 2012

Barcode

No barcode data available

Similar Products You Might Like

Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal
85% match

Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal

Springer

£179.99 31 May 2026
Chemokines and Cancer (Contemporary Cancer Research)
83% match

Chemokines and Cancer (Contemporary Cancer Research)

Humana

£120.92 31 May 2026
Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)
82% match

Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)

Springer

£111.46 31 May 2026
Inflammation, Aging and Cancer: Biological Injustices to Molecular Village of Immunity that Guard Health
82% match

Inflammation, Aging and Cancer: Biological Injustices to Molecular Village of Immunity that Guard Health

Springer

£109.14 01 Jul 2026
Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology)
81% match

Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology)

Humana

£107.98 29 May 2026
Suppression and Regulation of Immune Responses: Methods and Protocols: 677 (Methods in Molecular Biology, 677)
81% match

Suppression and Regulation of Immune Responses: Methods and Protocols: 677 (Methods in Molecular Biology, 677)

Humana

£74.05 11 Jun 2026
Innate and Adaptive Immunity in the Tumor Microenvironment: 1
81% match

Innate and Adaptive Immunity in the Tumor Microenvironment: 1

Springer

£75.53 22 Jun 2026
Clinical Cellular Immunology: Molecular and Therapeutic Reviews (Contemporary Immunology)
81% match

Clinical Cellular Immunology: Molecular and Therapeutic Reviews (Contemporary Immunology)

Humana

£77.89 12 Jun 2026
Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)
81% match

Advances in Tumor Immunology and Immunotherapy (Current Cancer Research)

Springer

£108.92 10 Jun 2026
Experimental and Applied Immunotherapy
80% match

Experimental and Applied Immunotherapy

Humana

£118.30 04 Jun 2026
Experimental and Applied Immunotherapy
80% match

Experimental and Applied Immunotherapy

Humana

£140.31 04 May 2026
Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology)
80% match

Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology)

Humana

£37.01 09 Jun 2026
Cancer Immunology: 30 (Immunology and Medicine, 30)
80% match

Cancer Immunology: 30 (Immunology and Medicine, 30)

Springer

£113.76 05 Jun 2026
Immunotherapy of Cancer: Methods and Protocols: 651 (Methods in Molecular Biology, 651)
79% match

Immunotherapy of Cancer: Methods and Protocols: 651 (Methods in Molecular Biology, 651)

Humana

£103.24 25 May 2026
Diet and Human Immune Function (Nutrition and Health)
79% match

Diet and Human Immune Function (Nutrition and Health)

Humana

£85.02 24 May 2026
General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology
79% match

General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology

Springer

£145.54 21 May 2026
Immunomodulation by Bacteria and Their Products
79% match

Immunomodulation by Bacteria and Their Products

Springer

£76.28 25 May 2026
Inflammation, Infection, and Microbiome in Cancers: Evidence, Mechanisms, and Implications (Physiology in Health and Disease)
79% match

Inflammation, Infection, and Microbiome in Cancers: Evidence, Mechanisms, and Implications (Physiology in Health and Disease)

Springer

£108.91 05 Jun 2026
Insulin-like Growth Factors and Cancer: From Basic Biology to Therapeutics (Cancer Drug Discovery and Development)
79% match

Insulin-like Growth Factors and Cancer: From Basic Biology to Therapeutics (Cancer Drug Discovery and Development)

Humana

£107.57 26 May 2026
Gene and Cellular Immunotherapy for Cancer (Cancer Drug Discovery and Development)
79% match

Gene and Cellular Immunotherapy for Cancer (Cancer Drug Discovery and Development)

Humana

£107.98 11 Jun 2026
Tumour-Associated Macrophages
79% match

Tumour-Associated Macrophages

Springer

£107.98 29 May 2026
Natural Killer Cells: At the Forefront of Modern Immunology
79% match

Natural Killer Cells: At the Forefront of Modern Immunology

Springer

£108.92 05 Jun 2026
Therapeutic Interventions in the Complement System (Contemporary Immunology)
79% match

Therapeutic Interventions in the Complement System (Contemporary Immunology)

Humana

£74.50 01 Jun 2026
Immunosurveillance, Immunodeficiencies and Lymphoproliferations: Lymphoproliferative Disorders in Congenital and Acquired Immunodeficiencies: 159 (Recent Results in Cancer Research, 159)
79% match

Immunosurveillance, Immunodeficiencies and Lymphoproliferations: Lymphoproliferative Disorders in Congenital and Acquired Immunodeficiencies: 159 (Recent Results in Cancer Research, 159)

Springer

£74.06 24 May 2026